• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Flomenberg Neal

    2/16/24 5:12:54 PM ET
    $LGST
    Blank Checks
    Finance
    Get the next $LGST alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Flomenberg Neal

    (Last) (First) (Middle)
    C/O TEVOGEN BIO HOLDINGS INC.
    15 INDEPENDENCE BLVD, STE 410

    (Street)
    WARREN NJ 07059

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    02/14/2024
    3. Issuer Name and Ticker or Trading Symbol
    Tevogen Bio Holdings Inc. [ TVGN ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Scientific Officer
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    See Exhibit 24.1 - Power of Attorney
    No securities are beneficially owned.
    /s/ Kirti Desai, Attorney-in-Fact 02/16/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $LGST alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LGST

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $LGST
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Desai Kirti was granted 9,696,186 shares (SEC Form 4)

    4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

    2/16/24 5:30:03 PM ET
    $LGST
    Blank Checks
    Finance

    Goh Keow Lin was granted 193,923 shares (SEC Form 4)

    4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

    2/16/24 5:29:11 PM ET
    $LGST
    Blank Checks
    Finance

    Patton Curtis L. was granted 969,618 shares (SEC Form 4)

    4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

    2/16/24 5:28:35 PM ET
    $LGST
    Blank Checks
    Finance

    $LGST
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tevogen Bio Holdings Inc., a Cell Therapy Company, Announces Completion of Business Combination and is to be Listed on Nasdaq Under Ticker TVGN

    Listing on Nasdaq is expected to provide Tevogen Bio Holdings Inc. increased access to capital to accelerate development of its genetically unmodified off-the-shelf T cell therapy products for large patient populations. WARREN, N.J., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. ("Tevogen Bio"), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and neurology, has announced the completion of Tevogen Bio Inc's previously announced business combination with Semper Paratus Acquisition Corporation, leading to the formation of Tevogen Bio Holdings Inc. The combined company's common s

    2/14/24 3:55:00 PM ET
    $LGST
    Blank Checks
    Finance

    Semper Paratus Acquisition Corporation's Shareholders Approve Business Combination with Tevogen Bio

    New York, NY, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Semper Paratus Acquisition Corporation ("Semper Paratus") (NASDAQ:LGST, LGSTW, LGSTU))), a publicly-traded special purpose acquisition company, announced today that its shareholders have approved the proposed business combination (the "Business Combination") with Tevogen Bio Inc, a Delaware corporation ("Tevogen Bio"), at an extraordinary general meeting of Semper Paratus' shareholders that was held on Wednesday, January 31, 2024 (the "Meeting"). Each of the proposals presented at the Meeting was approved, and the Business Combination is expected to be consummated as soon as practicable following the satisfaction or waiver of the remaining c

    2/1/24 8:15:00 AM ET
    $LGST
    Blank Checks
    Finance

    Semper Paratus Acquisition Corporation Announces Anticipated Listing of Tevogen Bio Holdings Inc. on Nasdaq

    New York, NY, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Semper Paratus Acquisition Corporation ("Semper Paratus") (NASDAQ:LGST, LGSTW))), a publicly-traded special purpose acquisition company, today announced that it has filed a supplement ("Prospectus Supplement") to its definitive proxy statement/prospectus dated January 10, 2024 (the "Proxy Statement/Prospectus") for the solicitation of proxies in connection with the extraordinary general meeting of Semper Paratus' shareholders scheduled to be held on January 29, 2024, to consider and vote on, among other proposals as more fully set forth in the Proxy Statement/Prospectus, the transactions (collectively, the "Business Combination") contemplated

    1/24/24 4:05:00 PM ET
    $LGST
    Blank Checks
    Finance

    $LGST
    SEC Filings

    View All

    Semper Paratus Acquisition Corporation filed SEC Form 8-K: Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics, Financial Statements and Exhibits

    8-K - Tevogen Bio Holdings Inc. (0001860871) (Filer)

    2/21/24 4:30:46 PM ET
    $LGST
    Blank Checks
    Finance

    Semper Paratus Acquisition Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Unregistered Sales of Equity Securities, Financial Statements and Exhibits (Amendment)

    8-K/A - Tevogen Bio Holdings Inc. (0001860871) (Filer)

    2/20/24 8:57:33 AM ET
    $LGST
    Blank Checks
    Finance

    SEC Form 8-A12B filed by Semper Paratus Acquisition Corporation

    8-A12B - Semper Paratus Acquisition Corp (0001860871) (Filer)

    2/14/24 5:20:14 PM ET
    $LGST
    Blank Checks
    Finance

    $LGST
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Semper Paratus Acquisition Corporation

    SC 13D - Tevogen Bio Holdings Inc. (0001860871) (Subject)

    2/22/24 8:13:20 PM ET
    $LGST
    Blank Checks
    Finance

    SEC Form SC 13D filed by Semper Paratus Acquisition Corporation

    SC 13D - Tevogen Bio Holdings Inc. (0001860871) (Subject)

    2/22/24 8:09:42 PM ET
    $LGST
    Blank Checks
    Finance

    SEC Form SC 13G/A filed by Semper Paratus Acquisition Corporation (Amendment)

    SC 13G/A - Semper Paratus Acquisition Corp (0001860871) (Subject)

    2/14/24 4:58:16 PM ET
    $LGST
    Blank Checks
    Finance